Abstract Details

Title Trends in Outcomes and Hospitalization Costs among Pediatric Myasthenia Gravis Patients in the United States. Data from Kids' Inpatient Database (KID) 1997-2009

Topic Muscle Disease/Neuromuscular Junction

Presentation(s) P02 - (-)

Poster/Presentation
Number 207

Objective

Background BACKGROUND: Advances in understanding of MG has led to the development of more effective therapeutic strategies including pulmonary support and mechanical ventilation.

Design/Methods DESIGN/METHODS: We determined the rates of occurrence, in-hospital outcomes, and mean hospital charges for pediatric patients hospitalized with MG from 1997 to 2009 using Kids' Inpatient Database (KID).

Results RESULTS: There was a steady increase in the number of MG patients from 1997 (144) to 2009 (319). The average patient age varied significantly, with a minimum of 11.9±5.7 years in 1997 and a maximum of 14.1±5.8 years in 2000 (p=0.014). Female predominance was observed in all time periods. The average length of stay was not significantly different from 1997 to 2009. The maximum average length of stay was 6.3±6.5 days in 1997 and the minimum was 4.7±5.4 days in 2003 (p=0.22). The vast majority of patients were discharged to home in all studied time periods. During the studied time periods there was only one death, which occurred in 2006. There was a significant increase in average hospital charges over time: $24,382±42,678 in 1997 and $51,109±68,370 in 2009 (p<0.001). This difference persisted after adjustment for inflation.

Conclusions CONCLUSIONS: There was a steady increase in the number of pediatric MG patients from 1997 to 2009. There was a significant increase in in-hospital charges of patients admitted for MG from 1997 to 2009, but without any significant variation in average length of stay, death rate, or disposition status.

Authors/Disclosures
Howard W. Sander, MD, FAAN PRESENTER	Dr. Sander has received personal compensation for serving as an employee of Grifols. Dr. Sander has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Law firm.
Rania A. Elenein, MD (Jefferson Health NJ)	Dr. Elenein has nothing to disclose.
Wenzhuan He, MD (UPMC Susquehanna Neurology)	Dr. He has nothing to disclose.
	No disclosure on file
Kottil W. Rammohan, MD (University of Miami)	Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. The institution of Dr. Rammohan has received research support from Genentech. The institution of Dr. Rammohan has received research support from Genzyme. The institution of Dr. Rammohan has received research support from EMD Serono. The institution of Dr. Rammohan has received research support from Alexion.
Zaid Al-Qudah, MD (Associate Specialist Inc.)	No disclosure on file
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��